New York A 11301: Relates to the commissioner's duty to ensure employers inform workers about certain provisions in employment contracts

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A11301 Summary:

BILL NOA11301 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORRules (Blumencranz)

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Add Art 27-EE §§2790 - 2799, §2803-cc, Pub Health L; amd §6530, Ed L

&nbsp

Establishes the "New York regenerative medicine advancement and patient protection act" to build framework for regenerative medicine and cell-based therapies; creates patient protections and disclosure requirements; authorizes limited physician use of qualifying regenerative medicine protocols; creates a regenerative medicine registry; establishes the New York regenerative medicine innovation program.

Go to top A11301 Actions:

BILL NOA11301 

&nbsp

05/11/2026referred to health

Go to topA11301 Committee&nbspVotes:

Go to topA11301 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA11301 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 11301

 IN ASSEMBLY

 May 11, 2026
 ___________

 Introduced by COMMITTEE ON RULES -- (at request of M. of A. Blumencranz)
 -- read once and referred to the Committee on Health

 AN ACT to amend the public health law and the education law, in relation
 to establishing a framework for regenerative medicine and cell-based
 therapies

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. This act shall be entitled the "New York regenerative medi-
 2 cine advancement and patient protection act."
 3 § 2. Legislative intent. The legislature hereby finds and declares
 4 that:
 5 1. Regenerative medicine, including cell-based and tissue-based thera-
 6 pies, has significant potential to improve healing, reduce pain, restore
 7 function, and advance treatment options for musculoskeletal injury,
 8 wound care, degenerative conditions, and other serious diseases.
 9 2. New York should lead the nation in responsible biomedical inno-
 10 vation by fostering ethical, transparent, and patient-centered access to
 11 regenerative medicine while maintaining robust safeguards against fraud,
 12 misrepresentation, unsafe products, and unethical sourcing.
 13 3. Patients deserve truthful advertising, meaningful informed consent,
 14 transparent disclosure of investigational status, and protection from
 15 deceptive or scientifically unsupported claims.
 16 4. Physicians and health systems in New York should have a clear state
 17 framework for the lawful provision of qualifying regenerative medicine
 18 services consistent with federal law, professional standards, and
 19 evidence-based practice.
 20 5. It is the intent of the legislature to promote innovation, attract
 21 research, support clinical excellence, and protect patients by creating
 22 a modern regulatory structure for regenerative medicine in New York
 23 state.
 24 § 3. The public health law is amended by adding a new article 27-EE to
 25 read as follows:
 26 ARTICLE 27-EE
 27 REGENERATIVE MEDICINE AND CELL-BASED THERAPIES

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD15450-01-6

 A. 11301 2

 1 Section 2790. Definitions.
 2 2791. Authorized use of qualifying regenerative medicine proto-
 3 cols.
 4 2792. Product sourcing and facility requirements.
 5 2793. Patient notice and informed consent.
 6 2794. Advertising and representations.
 7 2795. New York regenerative medicine registry.
 8 2796. Material adverse event reporting.
 9 2797. New York regenerative medicine innovation program.
 10 2798. Rulemaking.
 11 2799. Enforcement.
 12 § 2790. Definitions. As used in this article:
 13 1. "Regenerative medicine" means a therapeutic approach intended to
 14 repair, replace, restore, or regenerate human cells, tissues, or biolog-
 15 ic function, including cell-based therapies, tissue-based therapies,
 16 orthobiologics, and other human cells, tissues, and cellular and
 17 tissue-based products.
 18 2. "Human cells, tissues, and cellular and tissue-based products" or
 19 "HCT/Ps" shall have the same meaning as recognized under applicable
 20 federal law and regulation, including 21 C.F.R. Part 1271, as may be
 21 amended.
 22 3. "Qualifying regenerative medicine protocol" means a regenerative
 23 medicine treatment, procedure, or protocol that:
 24 a. i